Strength and weakness of genetic testing in clinical routine.
|
|
|
- Cameron Williamson
- 6 years ago
- Views:
Transcription
1 Strength and weakness of genetic testing in clinical routine. Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics Program, Langone Medical Center, New York University School of Medicine, New York, USA DISCLOSURES: Member of the advisory board of Transgenomics and GeneDX
2 Clinical value of molecular diagnosis in inherited arrhythmogenic diseases Define the specific genetic defect Confirm diagnosis in borderline cases/neonates Risk stratification Gene-specific therapy Identification of true sporadic cases Asymptomatic gene-carriers (penetrance) Strength and weaknesses are specific for each disease!
3 The clinical applicability of genetic testing in inherited disorders is disease-specific. Variables to be considered before counseling on the usefulness of genetic screening: Technical Success rate Size of genomic region to screen (number of genes) Clinical Relevance of pre-symptomatic diagnosis Relevance of identification of silent carriers Results influence risk stratification Results influence therapy/lifestyle Prenatal diagnosis is clinically justified Priori SG, Napolitano C - Circulation 2006
4 Strength and Weaknesses of genetic testing in LQTS
5 Multiple genes and mechanisms for similar phenotypes LQTS
6 What to expect from genetic testing in LQTS Disease Yield of Genetic Test LQTS 75% (80%) % of Controls with a Rare VUS 4% (LQT1,2,3) HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
7 Gene Locus Protein % of Disease Long QT Syndrome (LQTS) KCNQ1 (LQT1) 11p15.5 KCNH2 (LQT2) SCN5A (LQT3) KEY GENES IN LQTS 7q35-q36 3p21 I Ks potassium channel alpha subunit (Kv7.1) 30-35% I Kr potassium channel alpha subunit (Kv11.1 or herg) 25-40% Cardiac sodium channel alpha subunit (NaV1.5) 5-10% HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
8 Survival according to genotype in 580 genotyped patients Cumulative Survival (%) P= Genotype LQT1: LQT2: LQT3: Age (years) Priori et al NEJM 2003
9 Cardiac event free survival Event-free survival on Beta-blockers LQT1 LQT2 LQT Follow up (years) Priori et al. JAMA 2004
10 Clinical impact of genetic testing Disease Diagnostic Prognostic Therapeutic LQTS HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
11 Recommendations for genetic testing in LQTS Diseas e Confirmed Diagnosis/ Symptomatic Asymptomatic Family members LQTS RECOMMENDED KCNQ1, KCNH2, and SCN5A RECOMMENDED QT>500(480 Ped) Otherwise MAY BE indicated RECOMMEDED HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
12 Strength and Weaknesses of genetic testing in Brugada Syndrome
13 Brugada syndrome genes Locus Gene Function Functional effect of mutants Relative prevalence BrS1 SCN5A Cardiac sodium channel alpha sub-unit (Nav1.5) BrS2 GPD1-L Glycerol-6-phosphatedehydrogenase BrS3 CACNA1c L-type calcium channel alpha subunit (Cav1.2) BrS4 CACNB2 L-type calcium channel beta subunit BrS5 SCN1B Cardiac sodium channel beta1 subunit BrS6 KCNE3 Transient outward current beta subunit BrS7 SCN3B Cardiac sodium channel beta3 subunit Loss of function-reduced Na + current 15-20% Loss of function-reduced Na + current 1-2% Loss of function-reduced Ca 2+ current 7-10% Loss of function-reduced Ca 2+ current Loss of function-reduced Na + current 1% Gain of function-increased K + Ito current Loss of function-reduced Na + current? 1%? BrS8 MOG1 Nav1.5 trafficking control Loss of function-reduced Na + current <1%? BrS9 KCNE5 Transient outward (Kv4.3) beta subunnit Increased Ito 1%?
14 Only ONE KEY gene Gene Locus Protein Brugada Syndrome SCN5A 3p21 % of Disease Cardiac sodium channel alpha subunit (NaV1.5) 20-30% HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
15 Clinical impact of genetic testing Disease Diagnostic Prognostic Therapeutic BrS HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
16 Recommendations for genetic testing in Brugada Syndrome Diseas e Confirmed Diagnosis/ Symptomatic Asymptomatic BrS CAN BE USEFUL Not indicated if type 2 or 3 Family members RECOMMENDED HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
17 Strength and Weaknesses of genetic testing in Catecholaminergic Ventricular Tachycardia
18 CPVT genes AUTOSOMAL DOMINANT Ryanodine Receptor (RyR2) AUTOSOMAL RECESSIVE Calsequestrin (CASQ2)
19 The KEY CPVT genes Gene Locus Protein % of Disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Ryanodine RYR2 (CPVT1) 1q42.1-q43 Receptor 2 60% HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
20 VARIANTS OF UNKNOWN SIGNIFICANCE IN RyR2 Disease Yield of Genetic Test % of Controls with a Rare VUS CPVT 60% (70%) 3% HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
21 Clinical impact of genetic testing in CPVT Disease Diagnostic Prognostic Therapeutic CPVT HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
22 Clinical value of genetic testing Genetic testing at present time does not have the same indication in all inherited arrhythmias. In some conditions genetic testing is indicated to allow more accurate screening of family members & to identify carriers of disease-causing mutations In other conditions results of genetic testing bears implications for risk stratification and management In some diseases genetic testing is not yet ready for clinical use. As knowledge increases the impact of genetic testing will increase
23 Michael J. Ackerman, MD, PhD, Silvia G Priori, MD, PhD, Stephen Willems, MD, PhD, Co-Chairs Charles Berul,MD Ramon Brugada, MD, PhD Hugh Calkins, MD Eric Schulze-Bahr, MD, PhD, John A Camm, MD Chris Semsarian, MBBS, PhD Patrick Ellinor, MD PhD Jeffrey Towbin, MD Michael Gollob, MD Hugh Watkins, MD, PhD Robert Hamilton, MD Arthur Wilde, MD, PhD Ray Hershberger,MD Christian Wolpert, MD Dan Judge, MD Douglas Zipes, MD Hervè Le Marec, MD HRS / EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies in press 2011
Genetic testing in Cardiomyopathies
Genetic testing in Cardiomyopathies Silvia Giuliana Priori Cardiovascular Genetics, Langone Medical Center, New York University School of Medicine, New York, USA and Molecular Cardiology, IRCCS Fondazione
Silvia G Priori MD PhD
Novel therapies for the long QT syndrome. Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy and Leon Charney Division of Cardiology, Cardiovascular Genetics Program,
Genetic Testing for Cardiac Ion Channelopathies
Genetic Testing for Cardiac Ion Channelopathies Policy Number: 2.04.43 Last Review: 11/2018 Origination: 6/2007 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
Genetics of Sudden Cardiac Death. Geoffrey Pitt Ion Channel Research Unit Duke University. Disclosures: Grant funding from Medtronic.
Genetics of Sudden Cardiac Death Geoffrey Pitt Ion Channel Research Unit Duke University Disclosures: Grant funding from Medtronic Duke U N I V E R S I T Y Sudden Cardiac Death High incidence 50-100 per
Pearls of the ESC/ERS Guidelines 2015 Channelopathies
Pearls of the ESC/ERS Guidelines 2015 Channelopathies Carina Blomstrom Lundqvist Dept Cardiology, Uppsala, Sweden Content 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
HCM GENETIC OR CLINICAL FAMILY SCREENING?
HCM GENETIC OR CLINICAL FAMILY SCREENING? Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens GENETICS IN HCM DIAGNOSIS GENETIC RECOMFIRMATION
The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes
The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes RHEA C. PIMENTEL, MD, FACC, FHRS UNIVERSITY OF KANSAS HOSPITAL MID AMERICA CARDIOLOGY AUGUST 19, 2012 Monogenic Arrhythmia Syndromes Mendelian
Silvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Testing for Page 1 of 29 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Testing for Professional Institutional Original Effective Date: August 12,
Description. Page: 1 of 31. Genetic Testing for Cardiac Ion Channelopathies. Last Review Status/Date: December 2015
Genetic Testing for Cardiac Ion Last Review Status/Date: December 2015 Genetic Testing for Cardiac Ion Description Page: 1 of 31 Genetic testing is available for patients suspected of having cardiac ion
Corporate Medical Policy
Corporate Medical Policy Genetic Testing for Cardiac Ion Channelopathies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_cardiac_ion_channelopathies 10/2008 4/2018
Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD
Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD University of Pittsburgh Medical Center Pittsburgh, PA International Symposium of Inherited Arrhythmia Disorders and Hypertrophic
J. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam, the Netherlands
Inherited arrhythmia syndromes I: What you always wanted to know, but were afraid to ask: The basics of inherited arrhythmia syndromes and gene:cs J. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam,
Genetic Testing for Cardiac Ion Channelopathies. Description
Genetic Testing for Cardiac Ion Page: 1 of 30 Last Review Status/Date: March 2017 Genetic Testing for Cardiac Ion Description Genetic testing is available for patients suspected of having cardiac ion channelopathies
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies This document was developed as a partnership between the Heart Rhythm Society (HRS) and
Prolonged QT Syndromes: Congenital and Acquired
Prolonged QT Syndromes: Congenital and Acquired April 30, 2014 Elizabeth S. Kaufman, MD I have no financial disclosures. MetroHealth Campus, Case Western Reserve University Prolonged QT Syndromes Congenital
Protocol. Genetic Testing for Cardiac Ion Channelopathies
Protocol Genetic Testing for Cardiac Ion Channelopathies (20443) Medical Benefit Effective Date: 04/0/8 Next Review Date: /8 Preauthorization Yes Review Dates: 05/09, 05/0, 03/, 03/2, 03/3, 03/4, 03/5,
Name of Presenter: Marwan Refaat, MD
NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010 I have no actual or potential conflict of interest in relation
Ionchannels and channelopaties in the heart. Viktória Szőts
Ionchannels and channelopaties in the heart Viktória Szőts Action of membrane transport protein ATP-powered pump Ion chanels Transporters 10 1-10 3 ions/s 10 7-10 8 ions/s 10 2-10 4 ions/s Cardiac K +
Preventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete
Preventing Sudden Death in Young Athletes Ronn E. Tanel, MD Director, Pediatric Arrhythmia Service UCSF Children s Hospital Associate Professor of Pediatrics UCSF School of Medicine Outline Sudden death
Ionchannels and channelopaties in the heart
Ionchannels and channelopaties in the heart Csatorna müködés Több betegség Drugok kapcsolodása csat.hoz Sejtekbe ioncsat.expresszios módszerek, bemutatása Viktória Szőts Action of membrane transport protein
Genetic Testing for Cardiac Ion Channelopathies
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Genetic Testing for Page 1 of 23 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Genetic Testing for Professional Institutional Original Effective Date: August
Medical Policy. Description/Scope. Rationale
Subject: Document #: Current Effective Date: 03/29/2017 Status: Reviewed Last Review Date: 02/02/2017 Description/Scope This document addresses genetic testing of cardiac ion channel mutations in persons
Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?
Innovations in Interventional Cardiology and Electrophysiology Thessaloniki 2014 Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? K. Letsas, MD, FESC
Section: Effective Date: Subsection: Original Policy Date: Subject: Page: Last Review Status/Date: Background
Genetic Testing for Cardiac Ion Last Review Status/Date: March 2014 Genetic Testing for Cardiac Ion Description Page: 1 of 22 Genetic testing is available for patients suspected of having cardiac ion channelopathies
Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Silvia G. Priori, MD, PhD; Carlo Napolitano, MD, PhD; Mirella Memmi, PhD; Barbara Colombi,
WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY
Learning Objectives to Disclose: To CRITIQUE the ICD and its role in the treatment of BrS, CPVT, and LQTS WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY Conflicts of Interest to Disclose: Consultant
ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ
ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ ΣΤΕΛΙΟΣ ΠΑΡΑΣΚΕΥΑÏΔΗΣ ΔΙΕΥΘΥΝΤΗΣ ΕΣΥ Α Καρδιολογική Κλινική ΑΠΘ, Νοσοκομείο ΑΧΕΠΑ, Θεσσαλονίκη NO CONFLICT OF INTEREST Sudden Cardiac Death
Long Q. Long QT Syndrome. A Guide for
Long Q Long QT Syndrome A Guide for Introduction Long QT syndrome (LQTS) is a genetic heart disorder due to the malfunction of cardiac ion channels that results in 4,000 deaths annually in the United States
What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment. Andreas Pflaumer
What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment Andreas Pflaumer Diagnosis of CPVT Induction of different types of VES or VT by exercise or catecholamines AND exclusion of of other
Long QT. Long QT Syndrome. A Guide for Patients
Long QT Long QT Syndrome A Guide for Patients Long QT Syndrome What is long QT syndrome? Long QT syndrome (LQTS) is a condition that affects the ability of the heart to beat (contract) regularly and efficiently.
Genetic Testing for Congenital Long QT Syndrome
Genetic Testing for Congenital Long QT Syndrome Policy Number: 2.04.43 Last Review: 11/2013 Origination: 6/2007 Next Review: 11/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
Hereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases
Hereditary Cardiovascular Conditions genetic testing for undiagnosed diseases What is Hypertrophic Cardiomyopathy (HCM)? normal heart heart with hcm Extra or thick heart muscle Typically in the left ventricle
Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing
Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing Rong Bai, MD *, ; Carlo Napolitano, MD, PhD * ; Raffaella Bloise, MD * ; Nicola Monteforte,
State of the Molecular Autopsy
State of the Molecular Autopsy Michael J. Ackerman, MD, PhD Windland Smith Rice Cardiovascular Genomics Research Professor Professor of Medicine, Pediatrics, and Pharmacology Director, Long QT Syndrome/Genetic
Wojciech Szczepański, MD, PhD Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division Medical University of Bialystok
Channelopathies: - Long QT syndrome - Short QT syndrome - Brugada syndrome - Early repolarization syndrome - Catecholaminergic polymorphic ventricular tachycardia Wojciech Szczepański, MD, PhD Department
The Genetics and Prevention of Sudden Cardiac Death
The Genetics and Prevention of Sudden Cardiac Death Sudden cardiac death (SCD), a serious public health problem Every day, between 1,600 and 2,000 people die worldwide from genetically caused SCD. 1 SCD
Case studies in Channelopathies
Case studies in Channelopathies FABRICE CHOUTY, MD MEDICAL DIRECTOR HANNOVER-LIFE RE, PARIS (F) INTRODUCTION Thanks to the invasive electrophysiology and the progress of imaging techniques as well as the
CHANNELOPATHIES IS GENETIC TESTING ESSENTIAL IN PTS MANAGEMENT
CHANNELOPATHIES IS GENETIC TESTING ESSENTIAL IN PTS MANAGEMENT Inherited and Rare Cardiac Diseases Unit Heart Center for the Young and Athletes ONASSIS CARDIAC SURGERY CENTRE DIAGNOSIS ION CHANNEL DISEASE
Family stories: to illustrate inheritance and the impact on families. Dr Claire Turner Consultant clinical geneticist
Family stories: to illustrate inheritance and the impact on families Dr Claire Turner Consultant clinical geneticist Overview With respect to inherited cardiac conditions Simple modes of inheritance (Mendelian)
Invasive Risk Stratification: When is it needed?
Inherited Cardiomyopathies and Channelopathies: Who is at risk for Sudden Cardiac Death? Invasive Risk Stratification: When is it needed? Hung-Fat Tse, MD, PhD Department of Medicine The University of
Congenital long QT syndrome of particularly malignant course connected with so far unknown mutation in the sodium channel SCN5A gene
CASE REPORT Cardiology Journal 2013, Vol. 20, No. 1, pp. 78 82 10.5603/CJ.2013.0012 Copyright 2013 Via Medica ISSN 1897 5593 Congenital long QT syndrome of particularly malignant course connected with
How to manage a patient with short QT syndrome?
How to manage a patient with short QT syndrome? Torino, 27 ottobre2012 Carla Giustetto Division of Cardiology University of Torino QT 280 ms QTc 260 ms Narrow, tall and peaked T waves High incidence of
Active Cascade Screening in Primary Inherited Arrhythmia Syndromes
Journal of the American College of Cardiology Vol. 55, No. 23, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.12.063
Sudden cardiac death (SCD) accounts for 20% of mortality. Sudden Cardiac Death Compendium. Genetics of Sudden Cardiac Death
Sudden Cardiac Death Compendium Circulation Research Compendium on Sudden Cardiac Death The Spectrum of Epidemiology Underlying Sudden Cardiac Death Sudden Cardiac Death Risk Stratification Genetics of
Exercise-induced ventricular arrhythmias in CPVT patients occur at lower heart rate on beta-blocker therapy
Exercise-induced ventricular arrhythmias in CPVT patients occur at lower heart rate on beta-blocker therapy Leren IS, Haugaa KH, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, Früh A, Edvardsen T, Kongsgård
Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed LongQT Syndrome and Normal-Range Corrected QT Intervals
Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed LongQT Syndrome and Normal-Range Corrected QT Intervals Goldenberg, Ilan; Horr, Samuel; Moss, Arthur J.; Lopes, Coeli M.; Barsheshet,
Παναγιώτης Ιωαννίδης. Διευθυντής Τμήματος Αρρυθμιών & Επεμβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών
Διαστρωμάτωση κινδύνου για αιφνίδιο καρδιακό θάνατο σε ασθενείς που δεν συμπεριλαμβάνονται σε μεγάλες κλινικές μελέτες «Ασθενείς με ηλεκτρικά νοσήματα» Παναγιώτης Ιωαννίδης Διευθυντής Τμήματος Αρρυθμιών
Patient Resources: Cardiac Channelopathies
Patient Resources: Cardiac Channelopathies Overview of Cardiac Channelopathies: CPVT, Long QT Syndrome and Brugada Syndrome Heart muscle cells contract because of movement of certain molecules (called
Stage I: Binning Dashboard
Stage I: Binning Dashboard P[ GENE/GENE PANEL: KCNQ1, KCNH2, SCN5A DISORDER: Romano-Ward Long QT Syndrome HGNC ID: 6294, 6251, 10593 OMIM ID: 192500, 613688, 603830 ACTIONABILITY PENETRANCE 1. Is there
Is There a Genomic Basis to Acquired Channelopathic disease
Is There a Genomic Basis to Acquired Channelopathic disease Yaniv Bar-Cohen, M.D. Associate Professor of Pediatrics Division of Cardiology / Electrophysiology Children s Hospital Los Angeles Keck School
Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals
Journal of the American College of Cardiology Vol. 57, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.07.038
CONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT.
CONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT. SAHA Annual Congress 2017. Samkelo Jiyana, Adele Greyling, Andile Nxele, ZM,Makrexeni,L.Pepeta. BACKGROUND
Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies
Magi et al. Journal of Biomedical Science (2017) 24:56 DOI 10.1186/s12929-017-0364-6 REVIEW Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies Simona Magi 1*, Vincenzo
Professor Eric Schulze-Bahr
No CoI. Professor Eric Schulze-Bahr Institute for Genetics of Heart Diseases Department of Cardiology and Angiology University Hospital Münster / Germany ICD therapy in asymptomatic or borderline LQTS
Clinical Policy Title: Genetic testing for long QT syndrome (LQTS)
Clinical Policy Title: Genetic testing for long QT syndrome (LQTS) Clinical Policy Number: 04.01.02 Effective Date: Dec. 1, 2013 Initial Review Date: June 19, 2013 Most Recent Review Date: July 19, 2017
Adult Complexities of the Channelopathies
Adult Complexities of the Channelopathies Andrew Krahn MD FHRS Sauder Family and Heart and Stroke Foundation Chair in Cardiology Paul Brunes Chair in Heart Rhythm Disorders University of British Columbia
Brugada Syndrome: An Update
Brugada Syndrome: An Update Osama Diab Associate professor of Cardiology Ain Shams university, Cairo, Egypt Updates Mechanism and Genetics Risk stratification Treatment 1 Brugada syndrome causes 4 12%
Asymptomatic Long QT. Prof. Dr. Martin Borggrefe Mannheim
Asymptomatic Long QT Prof. Dr. Martin Borggrefe Mannheim QT interval Distribution of QTc intervals in large population-based studies Viskin S, Heart Rhythm 2009; 6: 711-715 QT interval Distribution of
The State of the Molecular Autopsy for Sudden Death in the Young
The State of the Molecular Autopsy for Sudden Death in the Young Michael J. Ackerman, MD, PhD Windland Smith Rice Cardiovascular Genomics Research Professor Professor of Medicine, Pediatrics, and Pharmacology
Declaration of conflict of interest. I have nothing to disclose.
Declaration of conflict of interest I have nothing to disclose. Left Bundle branch block in HF: DO GENETICS MATTER? Silvia Giuliana Priori Cardiovascular Genetics, Langone Medical Center, New York University
Key role of the molecular autopsy in sudden unexpected death
CONTEMPORARY REVIEW Key role of the molecular autopsy in sudden unexpected death Christopher Semsarian, MBBS, PhD,* Robert M. Hamilton, MD, CCDS From *Agnes Ginges Centre for Molecular Cardiology, Centenary
Genomics and Cardiac Arrhythmias
Journal of the American College of Cardiology Vol. 47, No. 1, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.08.059
When VF is the endpoint, wait and see is not always the best option.
Being free of symptoms does not necessarily mean free of arrhythmias. This Holter is from a asymptomatic 48 years old female with LQT2 When VF is the endpoint, wait and see is not always the best option.
HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital
HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital 1 2 Sudden death an unexpected natural death within a short time period, generally 1 hour or less from the onset
Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.
Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart. Hanne Rasmusen Consultant cardiologist, PhD Dept. of Cardiology Bispebjerg University Hospital
TABLE 1. Mutations in the Cardiac Ryanodine Receptor Gene (RyR2) Associated With CPVT and ARVD2* Amino acid Nucleotide Disease Families Familial? Doma
EDITORIAL Sudden Unexplained Death Caused by Cardiac Ryanodine Receptor (RyR2) Mutations About 10% to 20% of postmortem examinations of young people who were apparently healthy but died suddenly and unexpectedly
SEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !
Sudden cardiac death in the adult Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel.! " # $ % Cancers National Vital Statistics Report, Vol 49 (11), Oct. 12, 2001. 20% 25% State-specific
Risk Stratification in the Long-QT Syndrome
The new england journal of medicine original article Risk Stratification in the Long-QT Syndrome Silvia G. Priori, M.D., Ph.D., Peter J. Schwartz, M.D., Carlo Napolitano, M.D., Ph.D., Raffaella Bloise,
Catecholaminergic Polymorphic Ventricular Tachycardia
1 of 32 23/02/2016 20:22 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA):
Hereditary Conditions Predisposing to Sudden Death
Hereditary Conditions Predisposing to Sudden Death Barry London, MD PhD University of Pittsburgh Medical Center Pittsburgh, PA SCAA/HRS/UPMC Symposium Managing the Patient at Risk for Sudden Death 10/08/10
Genetics of Atrial Fibrillation: does it help in treatment decisions?
Genetics of Atrial Fibrillation: does it help in treatment decisions? Atrial fibrillation Pathophysiology of atrial fibrillation (AF) Genetic loci identified for AF Role in therapy outcome ardiologie Molecular
The Brugada syndrome is an arrhythmogenic disease
Value of Electrocardiographic Parameters and Ajmaline Test in the Diagnosis of Brugada Syndrome Caused by SCN5A Mutations Kui Hong, MD, PhD; Josep Brugada, MD, PhD; Antonio Oliva, MD; Antonio Berruezo-Sanchez,
Rhythm and Blues Drugs and QT Prolongation
Rhythm and Blues Drugs and QT Prolongation Dr Martin Quinn St Vincents University Hospital Irish Medication Safety Network conference Farmleigh 18 Oct 2013 Drugs and QT Prolongation Anti-psychotic, antidepressant,
Asaad Khoury 2,3 MD, Monther Boulos 1,3 MD, Mahmoud Suleiman 1,3 MD, Miry Blich 1,3 MD, Michael Eldar 4 MD, Ibrahim Marai 1,3 MD,
Flecainide therapy suppresses exercise induced ventricular arrhythmias in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia Asaad Khoury 2,3 MD, Monther Boulos 1,3 MD,
The congenital long-qt syndrome (LQTS) is an inherited
Clinical Implications for Affected arents and Siblings of robands With Long-QT Syndrome John Kimbrough, MD, hd; Arthur J. Moss, MD; Wojciech Zareba, MD, hd; Jennifer L. Robinson, MS; W. Jackson Hall, hd;
The impact of clinical and genetic findings on the management of young Brugada Syndrome patients
12 ème Congrès Médico-Chirugical de la FCPC 21 au 24 novembre 2015 Schoelcher, Martinique The impact of clinical and genetic findings on the management of young Brugada Syndrome patients Institut du Thorax,
FEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: None Genetic Testing for Cardiac Ion Channelopathies Description Genetic testing is available for patients suspected of having
Clinical Policy Title: Genetic testing for long QT syndrome (LQTS)
Clinical Policy Title: Genetic testing for long QT syndrome (LQTS) Clinical Policy Number: 04.01.02 Effective Date: Dec. 1, 2013 Initial Review Date: June 19, 2013 Most Recent Review Date: July 20, 2016
Sudden Unexplained Death in Epilepsy (SUDEP) and Dravet Syndrome
2016 DSF Biennial Family and Professional Conference Coral Gables, FL June 23-26, 2016 Sudden Unexplained Death in Epilepsy (SUDEP) and Dravet Syndrome Ronald J. Kanter, MD Director, Cardiac Electrophysiology,
CME Article Brugada pattern masking anterior myocardial infarction
Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University
Sudden cardiac death is a common outcome of several
Sudden Cardiac Death Sudden Cardiac Death and Genetic Ion Channelopathies Long QT, Brugada, Short QT, Catecholaminergic Polymorphic Ventricular Tachycardia, and Idiopathic Ventricular Fibrillation Carlo
Gene annotation for heart rhythm. 1. Control of heart rate 2. Action Potential 3. Ion channels and transporters 4. Arrhythmia 5.
Gene annotation for heart rhythm 1. Control of heart rate 2. Action Potential 3. Ion channels and transporters 4. Arrhythmia 5. EC coupling Control of heart rate Autonomic regulation of heart function
FANS Paediatric Pathway for Inherited Arrhythmias*
FANS Paediatric Pathway for Inherited Arrhythmias* The pathway is based on the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes
Genetics of cardiomyopathy and channelopathy
Genetics of cardiomyopathy and channelopathy Heart Failure Research Center, Department of Experimental Cardiology, AMC, Amsterdam, The Netherlands Correspondence: C. R. Bezzina, Heart Failure Research
Code CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis
ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike. Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org August
Induced pluripotent stem cell derived cardiomyocytes in studies of inherited arrhythmias
Review series Induced pluripotent stem cell derived cardiomyocytes in studies of inherited arrhythmias Silvia G. Priori, 1,2,3 Carlo Napolitano, 1,3 Elisa Di Pasquale, 4,5 and Gianluigi Condorelli 4,5
Genetic Testing for Heredity Cardiac Disease
Clinical Appropriateness Guidelines Genetic Testing for Heredity Cardiac Disease EFFECTIVE DECEMBER 1, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2064-1217 Table of Contents Scope... 3
Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada
Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada Άννα Κωστοπούλου Επιμελήτρια Α Ωνάσειο Καρδιοχειρουργικό Κέντρο Τμήμα Ηλεκτροφυσιολογίας και Βηματοδότησης BrS: Diagnosis 5:10000 First described
Plotse hartdood & genetica
Onder spanning inspannen Utrecht, 17 April 2018 Plotse hartdood & genetica N. Hofman, PhD Academic Medical Centre Amsterdam, the Netherlands European Reference Network Network of centres in Europe sharing
CME REVIEW ARTICLE. Catecholaminergic Polymorphic Ventricular Tachycardia. Jessica J. Wall, MD, MPH* and Ramesh V. Iyer, MD
CME REVIEW ARTICLE Catecholaminergic Polymorphic Ventricular Tachycardia Jessica J. Wall, MD, MPH* and Ramesh V. Iyer, MD Abstract: Catecholaminergic polymorphic ventricular tachycardia is a rare cause
Genetic Testing in the Long QT Syndrome
ORIGINAL CONTRIBUTION Genetic Testing in the Long QT Syndrome Development and Validation of an Efficient Approach to Genotyping in Clinical Practice Carlo Napolitano, MD, PhD Silvia G. Priori, MD, PhD
Are there low risk patients in Brugada syndrome?
Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the
Η γενετική διερεύνηση είναι απαραίτητη στην κλινική διαχείριση ασθενών με καναλοπάθειες
Η γενετική διερεύνηση είναι απαραίτητη στην κλινική διαχείριση ασθενών με καναλοπάθειες Ε.Χατζηνικολάου-Κοτσάκου Ηλεκτροφυσιολόγος-Επεμβατική Καρδιολόγος ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ-ΘΕΣΣΑΛΟΝΙΚΗ To be honest this
Cardiac arrhythmias are associated with high morbidity
Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies Pietro Enea Lazzerini, MD; Pier Leopoldo Capecchi, MD;* Nabil El-Sherif, MD;* Franco Laghi-Pasini, MD;* Mohamed Boutjdir,
Review Article Genetics of Inherited Arrhythmias in Children
www.ipej.org S20 Review Article Genetics of Inherited Arrhythmias in Children Maully J. Shah, MBBS Director, Interventional Electrophysiology, The Cardiac Center, The Children's Hospital of Philadelphia,
Genetic Basis of Ventricular Arrhythmias
Genetic Basis of Ventricular Arrhythmias Tim Boussy, MD a, *, Gaetano Paparella, MD a, Carlo de Asmundis, MD a, Andrea Sarkozy, MD a, Gian Battista Chierchia, MD a, Josep Brugada, MD, PhD b, Ramon Brugada,